contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


karolinska-developments-portfolio-company-umecrine-cognition-provides-update-on-ongoing-phase-1b2a-clinical-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Karolinska Development is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. Karolinska Development was founded in 2003 and is headquartered in Solna, Sweden.

Karolinska Development

STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing...

STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. Due to technical issues in the production of capsules used in the study, the clinical trial has been delayed. No patient safety concerns have been noted, and Umecrine Cognition is working intensively together with its supplier to resolve the issue. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in a randomized, double-blind, placebo-controlled, clinical phase 1b/2a study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms. Karolinska Development's ownership in Umecrine Cognition amounts to 73%. For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: <a href="https://www.globenewswire.com/Tracker?data=liDD2FNzEy5w0x8t7mcnMeO-xsDP5wuYE9MIVmJq2lJYJnWswE-nA8bstWEvU-ank5v1Y41ZCtcNf-U2KTpPXx4ff-nKiRHrKsXxwzgiTN0IioDOrbGFeeP41V4ssGI_uoZui0uPG80kF8USOQB4oUrNR3TaIPwUpMIwLYFfu9s=">viktor.drvota@karolinskadevelopment.com</a>&nbsp; Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB Phone: +46&nbsp;70&nbsp;207 48 26, e-mail: <a href="https://www.globenewswire.com/Tracker?data=BzzD6dolZLvSVTIBQXGeFbMS0NZPAzdFlXGlZT90vrxtz8haD1HGywi2i2uQe8xkQmXGVp19lV01ZmcTcbqZ4bmJGJqru2y37KsF82xbELDlLFv3S_DZ3R1Px7_sMoyYehHuYI_G6IZIoryZjrfBRA==">johan.dighed@karolinskadevelopment.com</a> TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=0M4NHTZ5ZUaelP5374BKgRSYAlvXqF_Tvm_R0KCyeLN-T_e03tAoSLyICwdVNwnN8oUMBHWJ5m_hfDo6AZ3kTT2-heANsfZYitgCOWe47JEoO-w0_Pa5eZvgb5E5RLmK">www.karolinskadevelopment.com</a>. Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/b93ef39c-925c-453e-9389-0d45c09ea124">KD Umecrine Cognition technical issues_eng</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA1NDU2MCM0MDIwNzc4MzkjMjAwMDcyNQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/MGIyMjFhNDktYTk3Mi00YjA1LTk2Y2ItODQwNzQxM2FiZjkzLTEwMTIyOTgtMjAyNS0wMy0xOC1lbg==/tiny/Karolinska-Development-AB-publ.png" alt="">

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study